Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Related Citations for PubMed (Select 23832820)

1.

A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index.

Bubis G, Hilly O, Bubis R, Halpern M, Schwartz A, Koren R, Rath-Wolfson L.

Pathol Oncol Res. 2013 Oct;19(4):875-9. doi: 10.1007/s12253-013-9655-8. Epub 2013 Jul 7.

PMID:
23832820
2.

Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.

Mohammadizadeh F, Ghasemibasir H, Rajabi P, Naimi A, Eftekhari A, Mesbah A.

Cancer Biomark. 2009;5(1):1-8. doi: 10.3233/CBM-2009-0551.

PMID:
19242056
3.

Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer.

Debald M, Kaiser C, Abramian A, Schildhaus HU, Locher P, Wolfgarten M, Kuhn W, Braun M.

Anticancer Res. 2013 May;33(5):1971-5.

PMID:
23645745
4.

Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma.

Choi YJ, Pinto MM, Hao L, Riba AK.

Mod Pathol. 2008 Oct;21(10):1224-37. doi: 10.1038/modpathol.2008.106. Epub 2008 Jun 27.

5.

Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.

Moll R, Mitze M, Frixen UH, Birchmeier W.

Am J Pathol. 1993 Dec;143(6):1731-42.

6.

Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters.

Hemalatha A, Suresh TN, Kumar ML.

Indian J Cancer. 2013 Jul-Sep;50(3):189-94. doi: 10.4103/0019-509X.118724.

7.

How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists.

Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, Obermann E, Ohlschlegel C, Padberg B, Rakozy C, Sancho Oliver S, Schobinger-Clement S, Schreiber-Facklam H, Singer G, Tapia C, Wagner U, Mastropasqua MG, Viale G, Lehr HA.

PLoS One. 2012;7(5):e37379. doi: 10.1371/journal.pone.0037379. Epub 2012 May 25.

8.

Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.

Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MD, Page DL.

Hum Pathol. 2001 May;32(5):487-93.

PMID:
11381366
9.

The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast.

Tan DS, Potts HW, Leong AC, Gillett CE, Skilton D, Harris WH, Liebmann RD, Hanby AM.

J Pathol. 1999 Sep;189(1):20-7.

PMID:
10451483
10.

p53 protein expression and proliferative activity in ductal breast carcinomas.

Ioakim-Liossi A, Safioleas M, Karakitsos P, Athanassiadou P, Athanassiades P, Gogas J, Nakopoulou L.

Cytopathology. 2000 Aug;11(4):255-61.

PMID:
10983725
11.

Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.

Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, Stipsanelli A, Dimitrakakis K, Marinopoulos S, Tsiouris S, Antsaklis A.

Breast Cancer. 2011 Oct;18(4):286-91. doi: 10.1007/s12282-009-0192-y. Epub 2010 Feb 9.

PMID:
20143189
12.

E-cadherin and beta-catenin expression in breast medullary carcinomas.

Charpin C, Bonnier P, Garcia S, Andrac L, Crebassa B, Dorel M, Lavaut MN, Allasia C.

Int J Oncol. 1999 Aug;15(2):285-92.

PMID:
10402239
13.

Relationship of p53, Bcl-2, Ki-67 index and E-cadherin expression in early invasive breast cancers with comedonecrosis as an accelerated apoptosis.

Hosaka N, Ryu T, Cui W, Li Q, Nishida A, Miyake T, Takaki T, Inaba M, Ikehara S.

J Clin Pathol. 2006 Jul;59(7):692-8. Epub 2006 Feb 10.

14.

MIB-1 (Ki-67) immunostaining of breast cancer cells in cytologic smears.

Dalquen P, Baschiera B, Chaffard R, Dieterich H, Feichter GE, Krmer K, Torhorst J.

Acta Cytol. 1997 Mar-Apr;41(2):229-37. Review.

PMID:
9100748
15.

Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count.

Lehr HA, Hansen DA, Kussick S, Li M, Hwang H, Krummenauer F, Trouet S, Gown AM.

Hum Pathol. 1999 Nov;30(11):1314-20.

PMID:
10571511
16.

Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.

Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M, Dziegiel P.

Folia Histochem Cytobiol. 2010 Sep 30;48(3):442-6. doi: 10.2478/v10042-010-0069-0.

17.
18.
20.

Her2 negative luminal breast carcinoma and Ki-67 evaluation.

Pavlakis K, Vrekoussis T, Tsipoura A, Tsenga A, Arapantoni-Dadioti P, Gavresea T, Messini I, Barbounis V.

Breast. 2012 Aug;21(4):529-33. doi: 10.1016/j.breast.2012.04.004. Epub 2012 May 28.

PMID:
22647834
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk